Presidential Advisory Council on HIV/AIDS, International Issues Subcommittee [Transcript]

17
1 the distinct minority.
2 If you go back to the transcript of that 1994
3 meeting where they made that decision, it's remarkable to
4 see that they had no one on that panel that could answer
5 basic questions like, "Are there any vaccines that have
6 been studied that have no immune correlates?" I mean,
7 there was nobody with any vaccine development experience
8 there.
9 It's also interesting that when they made that
10 decision in 1994 not to go forward with trials, they said,
11 "Well, we think in a year there will be some other vaccines
12 we can choose from that might seem more likely to succeed."
13 Now four years have gone by and some of the scientific
14 objections to those vaccines, that they didn't produce
15 neutralizing antibodies to primary isolates -- well, now
16 they have. Yet nobody is asking the question about why
17 don't we do a trial of these products now?
18 DR. MANN: May I make a proposal based on what
19 you just said? The vaccine committee that exists -- both
20 committees are NIH committees. That's basically like
21 saying that the whole process of vaccine development
22 belongs in one part of the whole process. Why isn't there
23 an HHS AIDS vaccine committee chaired by someone who has
24 experience developing vaccines, principally peopled by
25 people who have that experience, with some useful other
26 scientists bringing in other perspectives, and then also

FREILICHER & ASSOCIATES, COURT REPORTERS
[phone]